The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600
The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600
Auteur
Massi, D.. Division of Pathological Anatomy, Department of Surgery and Translational Medicine, University of Florence, Florence
Brusa, D.. Human Genetics Foundation (HuGeF), Turin
Merelli, B.. Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo
Falcone, C.. Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy
Xue, G.. Department of Biomedicine, University Hospital of Basel, Basel, Switzerland
Carobbio, A.. Department of Biomedicine, University Hospital of Basel, Basel, Switzerland
Nassini, R.. Unit of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence
Baroni, G.. Division of Pathological Anatomy, Department of Surgery and Translational Medicine, University of Florence, Florence
Tamborini, E.. Experimental Molecular Pathology, Department of Pathology, National Cancer Institute, Milan
Cattaneo, L.. Division of Pathological Anatomy, Papa Giovanni XXIII Hospital, Bergamo
Audrito, V.. Human Genetics Foundation (HuGeF), Turin
Deaglio, S.. Human Genetics Foundation (HuGeF), Turin
Mandalà, M.. Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo
Type de document
Postprint
Langue
Anglais
Publié dans
Annals of Oncology, 2015, vol. 26, no. 9, p. 1980-1987. Oxford University Press
In the present study, we have provided clinical evidence of the predictive and prognostic relevance of tumoral PD-L1 expression and density of immune cell infiltration in BRAFV600-mutated metastatic melanoma patients treated with BRAF inhibitors